VACCINATING CHILDREN AFTER CHEMOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA

Registry ID

SI02

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

CANADIAN IMMUNIZATION RESEARCH NETWORK (CIRN), DALHOUSIE UNIVERSITY

Start date

2015-07-21

Last update

2017-03-01

Conditions

• IMMUNIZATION
• ACUTE LYMPHOBLASTIC LEUKEMIA

Related clinical trials

• A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
• A MODULAR PHASE I/II, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, IMMUNOGENICITY, AND PRELIMINARY EFFICACY OF AZD4512 MONOTHERAPY OR IN COMBINATION WITH ANTICANCER AGENT(S) IN PARTICIPANTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
• RE-TREATMENT WITH SECOND GENERATION, ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS IN RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (ACIT001-3)
• A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AZD0486 IN ADOLESCENT AND ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA
• A RANDOMIZED TRIAL OF LEVOCARNITINE PROPHYLAXIS TO PREVENT ASPARAGINASE-ASSOCIATED HEPATOTOXICITY IN ADOLESCENTS AND YOUNG ADULTS RECEIVING ACUTE LYMPHOBLASTIC LEUKEMIA THERAPY
• A PHASE IB STUDY OF THE PHARMACOKINETICS, SAFETY AND EFFICACY OF ORALLY ADMINISTERED HQP1351 IN SUBJECTS WITH REFRACTORY CHRONIC MYELOID LEUKEMIA (CML) AND ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

View on source registry